ASH Poster Walks

ASH Poster Walk on Chemotherapy-Free Treatments for Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma Hosted by Blood Neoplasia

Sunday, December 7, 2025, 8:00 a.m. - 9:00 a.m.OCCC - West Halls B3-B4

Chemotherapy-free options are becoming increasingly available for patients with indolent and aggressive B-NHL. Multiple trials are investigating their safety and efficacy, finally challenging the paradigm that chemotherapy is here to stay. This is very significant not only for science, but also from a patient perspective. Spotlighting the most promising agents and combinations, which may change clinical practice in the near future, is now crucial.

Chair:

Paolo Strati, MD
The University of Texas MD Anderson Cancer Center

Speakers:

Ryan C Lynch
Fred Hutch Cancer Center
Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Aneeqa Zafar, MD
University of California, Davis
A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study

Swetha Thiruvengadam, MD
City of Hope
Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma

Li Wang III, Certified Doctor
Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology
A prospective, multicenter, randomized, controlled clinical trial comparing polatuzumab vedotin, zanubrutinib, lenalidomide, and rituximab (Pola-ZR2) versus zanubrutinib, lenalidomide, and rituximab (ZR2) in the treatment of previously untreated, elderly patients with diffuse large B-cell lymphoma (NCT06522555)

Manali Kamdar
Affiliation University of Colorado
Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Haiwen Huang Sr
The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology Suzhou
Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma

back to top

ASH Poster Walk on Inherited Bleeding Disorders Hosted by Blood Vessels, Thrombosis & Hemostasis

Saturday, December 6, 2025, 11:15 a.m. - 12:15 p.m.OCCC - West Halls B3-B4

This poster walk will showcase the latest clinical studies in inherited bleeding disorders, with a particular emphasis on advancements in diagnosis and management. Attendees will benefit from discussions focused on understanding novel diagnostic tools, personalized treatment approaches, and strategies to overcome barriers in care for conditions like hemophilia and von Willebrand disease. By highlighting the intersection of equity topics, such as women's health and global hematology, the walk aims to foster a more inclusive perspective on inherited bleeding disorders, ultimately promoting better patient outcomes worldwide. 

Chair:

Nathan Connell, MD,MPH
Brigham and Women's Hospital

Speakers:

Keiji Nogami
Nara Medical University
Ex vivo evaluation of the procoagulant effect of NXT007 prophylaxis in people with Hemophilia A without factor VIII inhibitors: Phase I/II study (NXTAGE)

Guy Young, MD
Children's Hospital Los Angeles
Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress

Fernando Corrales-Medina
University of Miami-Hemophilia and Thrombosis Comprehensive Treatment Center
A risk-based scoring approach to individualize prophylaxis in patients with Hemophilia A: Results from the predict study

Guillermo Tobaruela
F. Hoffmann-La Roche Ltd
RESHAPE: A non-interventional study of real-world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America, Eastern Europe, Africa, Asia, and the Middle East

Kadhim Al-Banaa
University of California San Diego Health
Perioperative use of efanesoctocog alfa in Hemophilia A: A dual-center real-world study

Travis Gould, PhD
Pfizer Inc
Management of breakthrough bleeds in participants with hemophilia ? or ? without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study

back to top

ASH Poster Walk on Leukemia in Latin America: Bridging Gaps in Genetics, Access, and Innovation Hosted by Global Hematology

Monday, December 8, 2025, 12:30 p.m. - 1:30 p.m.OCCC - West Halls B3-B4

This poster walk highlights the urgent need to improve leukemia outcomes in Latin America by addressing region-specific challenges in genetics, access to care, and treatment equity. Latin American populations are highly diverse and frequently underrepresented in global research, which limits the applicability of existing therapeutic protocols. The walk emphasizes the importance of generating region-specific data, studying local genetic profiles, and adapting emerging technologies in cost-effective and sustainable ways that match the reality of Latin American health systems. Attendees will gain a deeper understanding of existing gaps in research infrastructure, clinical trial participation, and access to innovative therapies. Ultimately, this poster walk aims to define concrete priorities for regional data generation, collaborative research, and sustainable implementation strategies to improve leukemia diagnosis and treatment in Latin America.

Chair:

Melanie Wendy Castro Mollo Jr
Dana Farber Cancer Institute

Speakers:

Macarena Salinas Roa
Hospital del Salvador
Outcomes and cause-specific mortality of AML in adults from Chile

Adriana Bornacelly, MD
Fundación Universitaria Ciencias de la Salud- FUCS
Automatic identification of blast leukemic cells types using deep learning with vision transformers.

Joaquin Garcia-Solorio I, PhD student
National Institute of Genomic Medicine (INMEGEN)
Ph-like B-cell acute lymphoblastic leukemia in a Mexican pediatric cohort: Molecular features and prognostic implications

Analy Mora
Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran
Induction mortality in acute leukemia: The hidden burden of infections in a middle-income country

Carolina Pavlovsky
FUNDALEU
Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients

Mariana Nassif Kerbauy I, Mariana Kerbauy
Einstein - Hospital Israelita
Outcomes of HLA-matched unrelated versus haploidentical hematopoietic cell transplantation in acute leukemia: A multicenter observational study in Brazil facilitated by the CIBMTR

back to top

ASH Poster Walk on Novel and Emerging Therapeutics in Erythrocyte and Iron Disorders Hosted by Blood Red Cells and Iron

Sunday, December 7, 2025, 11:15 a.m. - 12:15 p.m.OCCC - West Halls B3-B4

A more precise, mechanism-driven approach to treating red blood cell and iron/heme disorders is urgently needed. This poster walk showcases cutting-edge therapeutic strategies, from small-molecule activators and mRNA delivery platforms to gene-editing technologies and next-generation hemoglobin-modulating agents. These novel and emerging therapeutic strategies are designed to improve key disease parameters in disorders of erythropoiesis and iron metabolism, including Diamond–Blackfan anemia, autoimmune hemolytic anemia, hemochromatosis, sickle cell disease, and refractory thrombocytopenia.

Chair:

Patrick Gallagher, MD
Nationwide Childrens Hospital / Ohio State University

Laura Silvestri Jr
University Vita-Salute San Raffaele

Speakers:

Jonathan Roelof Adriaan de Wilde, PhD
UMC Utrecht
Activation of pyruvate kinase by mitapivat potentially rescues ineffective erythropoiesis in models of diamond blackfan anemia.

David Kuter, MD, DPhil
Massahusetts General Hospital
Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2)

Nermi Parrow
Saint Louis University School of Medicine
Delivery of HFE mRNA by lipid nanoparticles corrects iron parameters and BMP responsiveness in murine hereditary hemochromatosis

Sheinei Alan, MD, PhD
Inova Medical Center
Pociredir, a novel oral once-daily fetal hemoglobin inducer: Results from the Phase 1b pioneer study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness

Osheiza Abdulmalik, DVM
Perelman School of Medicine, University of Pennsylvania
Direct hemoglobin S polymerization inhibitor MCP435 completely halts ongoing disease pathophysiology in transgenic sickle cell disease mice

Hila Shaim
MD Anderson Cancer Center
GMP compliant CRISPR/Cas9 gene editing of B2 microglobulin in cord blood derived megakaryocytes and platelets for patients with refractory thrombocytopenia

back to top

ASH Poster Walk on Population Health and Access to Care

Wednesday, December 10, 2025, 10:00 a.m. - 11:00 a.m.ASH Virtual Platform

This Poster Walk will highlight works that investigate structural barriers impacting provision of care across hematology for patients from underserved or special populations. In particular, the walk will spotlight research (featured in the posters) that mitigates barriers and extends access to optimal care across populations. The featured posters will outline work being done to address unique care delivery challenges impacting patients, donors, and caregivers from specific vulnerable populations. It will serve to connect stakeholders in population health in hematology and facilitate discussions on the state of population health research in the field. 

Chair:

Warren Benjamin Fingrut, MD, MPH
The University of Texas MD Anderson Cancer Center

Speakers:

Maire Okoniewski
The University of Kansas Cancer Center
Social determinants of health and outcomes in patients with acute leukemia: Interim results from a prospective, single institution study

Colleen A. Kelly, MD
Dana-Farber Cancer Institute
The feasibility of collecting social determinants of health in the national multi-center GRASP sickle cell gene therapy trial

Megan Connor, MD
University of Colorado
Rethinking ferritin reference ranges for diagnosing iron deficiency at Denver health

James Yoon, MD
Memorial Sloan Kettering Cancer Center
Access to acute promyelocytic leukemia treatment in New York City

Shruti Prem Sudha
Bahrain Oncology Center
Clinical implications and prevalence of benign ethnic neutropenia (BEN) in lymphoma patients of middle eastern ethnicity

Alexander D. Sanjurjo, B.S.
Columbia University Vagelos College of Physicians and Surgeons
Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study

back to top

ASH Poster Walk on Rewiring Immune Effector Cells: Emerging Strategies to Boost Cancer Immunotherapy Hosted by Blood Immunology & Cellular Therapy

Monday, December 8, 2025, 8:00 a.m. - 9:00 a.m.OCCC - West Halls B3-B4

The tumor microenvironment presents significant metabolic and immunosuppressive challenges that limit the effectiveness of adoptive T cell therapies. Recent studies, including our work on the medium-chain fatty acid receptor GPR84, demonstrate that reprogramming T cell metabolism can enhance persistence, reduce exhaustion, and improve antitumor responses across various cancer models. This Poster Walk will bring together novel findings focused on metabolic modulation, cellular engineering, and immune reprogramming strategies that aim to optimize T cell function for therapeutic purposes. By highlighting innovative approaches, from receptor targeting to nutrient sensing and mitochondrial fitness, this session will benefit researchers and clinicians seeking next-generation solutions to enhance cancer immunotherapy. Attendees will gain insight into emerging mechanisms and translational strategies that can inform both preclinical and clinical development of improved T cell-based treatments.

Chair:

Anamaria Morales-Alvarez
University of Central Florida

Speakers:

Roman Shapiro, MD
Dana-Farber Cancer Institute
Development of a novel multiomic sequencing approach to characterize infused donor memory-like NK cells in an immune compatible environment

Andreia Maia
Dana-Farber Cancer Institute | Harvard Medical School
Reprogramming CAR-NK cells with IL-7/IL-7Ra to amplify STAT1 signaling and activate bystander T cells for enhanced immunotherapy

Keiki Nagaharu
Mie University
A long-term antigen-spreading by novel cancer vaccine with hyaluronic acid nanogel accelerate the anti-neoplastic efficacy of cytotoxicity of infused TCR-T cells and altered neplastic microenvironment

Supriya Chakraborty, PhD
Wake Forest University School Of Medicine
Pretargeted glycoengineered NK cell (PG-NK) therapy: A universal off-the-shelf platform redefining targeted cell therapy strategies in lymphoma

Xuying Pei
Peking University
A novel CD20-conjugated ?d T cell therapy via unnatural sugar-mediated chemical modification for the treatment of EBV-PTLD

Paula do Amaral Costa Ribeiro
Hospital das Clínicas HCFMUSP, Faculdade de Medicina, University of São Paulo, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31)
Differentiation of human induced pluripotent stem cells expressing chimeric antigen receptors into distinct immune cells as an off-the-shelf strategy for tumor treatments

back to top

ASH Poster Walk on State of the Art Artificial Intelligence in Hematology

Wednesday, December 10, 2025, 5:00 p.m. - 6:00 p.m.ASH Virtual Platform

Over the past decade, interest in developing artificial intelligence (AI) tools to augment clinical decision-making has surged. While the integration of these techniques into routine hematologic practice remains a developing frontier, the capacity for AI to refine disease diagnosis, prognosis, and therapeutic strategy is becoming increasingly evident. This Poster Walk highlights the trajectory of this rapidly growing field through six pivotal studies utilizing machine learning, computer vision, and large language models (LLMs). 

The session will examine foundational advancements, including federated learning frameworks for synthetic data generation and AI-driven platforms for identifying novel drug targets. We will further explore emerging clinical applications, such as enhancing acute leukemia management through long-read whole genome sequencing, automating the morphological diagnosis of cutaneous lymphoma, and utilizing machine learning to detect prognostic markers in CLL karyotypes. Finally, we will discuss the implementation of verifiable, guideline-based clinical decision support systems. Collectively, these works illustrate how AI is evolving from theoretical frameworks toward actionable clinical and translational applications. 

Chair:

Andrew Srisuwananukorn, MD
The Ohio State University Comprehensive Cancer Center

Speakers:

Gianluca Asti, MSc
Humanitas Clinical and Research Hospital, IRCCS
Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases

Craig Michael Forester, MD,PhD
University of Colorado-Anschutz
AI-driven platform voyager identifies a novel poison exon and splicing modulator to target specific degradation of STAT1

Anna Lux
University of Florida
Long-read whole genome sequencing improves clinical management in acute leukemia

Ali Kamali
Memorial Sloan Kettering Cancer Center
AI-based diagnosis of cutaneous lymphoma and lymphoproliferative disorders via H&E morphology and LLM-assisted cohort curation

Jiasheng Wang, MD
The Ohio State University Comprehensive Cancer Center
Artificial intelligence system for delivering interactive and verifiable guideline-based clinical decision support in hematology

Alessandro Baldi
MLL Munich Leukemia Laboratory
ML-driven analysis of iscn karyotypes enables detection of novel prognostic markers in chronic lymphocytic leukemia (CLL)